Clinical trial
Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes
NCT00190502 · Institute for Clinical and Experimental Medicine, Other · Unknown status
Key facts
| NCT number | NCT00190502 |
|---|---|
| Title | Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes |
| Official title | The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes |
| Lead sponsor | Institute for Clinical and Experimental Medicine, Other |
| Collaborators | Ministry of Health, Czech Republic |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | Polyclonal anti-T-cell antibodies |
| Enrollment | 28 |
| Start date | Nov 1, 2000 |
| Completion | Dec 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 9, 2007 |
| Countries | Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: